Key result
Calcium handling abnormalities are critical elements in atrial fibrillation pathophysiology and represent promising targets for novel therapeutics, though clinical implementation remains under investigation.
Calcium handling abnormalities are critical in atrial fibrillation pathophysiology and represent promising targets for novel therapeutics.
Does not support clinical adoption in AF; leaves open whether targeting calcium handling will yield effective therapies.
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a substantial impact on morbidity and mortality. Antiarrhythmic drugs play a major role in rhythm-control therapy of AF. However, currently available agents exhibit limited efficacy and pronounced adverse effects, notably drug-induced proarrhythmia. Recent experimental studies have identified that Ca handling abnormalities are critical elements in AF pathophysiology with central roles in atrial ectopic activity, reentry, and atrial remodeling suggesting that Ca handling abnormalities could be promising targets for novel AF therapeutics. Here, we summarize key aspects of AF-related Ca-handling abnormalities, describe currently available compounds targeting atrial Ca handling, and highlight potential novel targets and experimental drugs currently under investigation. Finally, we assess how close AF therapeutics based on Ca-handling abnormalities are to clinical implementation.
No takes yet. Share an insight, caveat, or question.
Heijman et al. (2015) conducted a review in Atrial fibrillation. Calcium handling targeted therapeutics was evaluated. Calcium handling abnormalities are critical elements in atrial fibrillation pathophysiology and represent promising targets for novel therapeutics, though clinical implementation remains under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: